AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00855257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02862548
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally
Trial: NCT03865511
Drug: TAGRISSO® 80mg (Osimertinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
Trial: NCT01617655
Drug: Placebo (for alirocumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Trial: NCT01617655
Drug: Lipid Modifying Therapy (LMT)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Trial: NCT02897869
Drug: POL7080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 doses of POL7080 alone over 2.5 days
Trial: NCT02897869
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of Amikacin alone over 2.5 days
Trial: NCT02897869
Drug: POL7080 + Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
Trial: NCT01965418
Drug: Fufang Biejia Ruangan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01965418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02621619
Drug: IV acetaminophen + 0.5 mg IV hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
Trial: NCT03917225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
Trial: NCT01332604
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral repeating dose
Trial: NCT01332604
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00680953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
Trial: NCT01081821
Drug: single dose NJ-39758979/ matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
Trial: NCT03172481
Drug: PRC-063 oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose
Trial: NCT03172481
Drug: Placebo oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose
Trial: NCT01684683
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 0.1 bid
Trial: NCT01684683
Drug: Placebo(for Theophylline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
Trial: NCT01705964
Drug: IM epinephrine 1:1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
Trial: NCT00387348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo pill identical in appearance to the escitalpram pill once daily
Trial: NCT00838461
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03342456
Drug: Doxycycline Hyclate Enteric-Coated Capsules
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
Trial: NCT00382213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00292747
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00292747
Drug: Ibuprofen Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02468206
Drug: Lauromacrogol
RxNorm normalized name: Lauromacrogol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00502528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-interventional
Trial: NCT02591888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
Trial: NCT02521298
Drug: Cortico-Steroid Injection. Depomedrol 40mg/1ml.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02310906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP-4053 placebo-matching solution for IV infusion.
Trial: NCT04164329
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
Trial: NCT02119026
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance
Trial: NCT02119026
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 bid d1-14,
Trial: NCT00703469
Drug: MDX1106-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00703469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT02022033
Drug: FOLFOXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)
Trial: NCT01524237
Drug: LY2979165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally
Trial: NCT02471911
Drug: KPT-330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
Trial: NCT01409993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo three times a day for three months
Trial: NCT00141180
Drug: CP-481,715
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02994381
Drug: RPC1063
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01372449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01803711
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01803711
Drug: Placebo (for Omega 3 fatty acid supplement)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03746067
Drug: TS-134
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, 10 mg, or 20 mg oral solution
Trial: NCT03746067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo oral solution
Trial: NCT04202549
Drug: intra-arterial cocktail therapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
Trial: NCT00185354
Drug: BAY86-5016, SH P00331F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
Trial: NCT00002718
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01519401
Drug: 3 mg drospirenone and 20 µg ethinyl-estradiol
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01519401
Drug: 3 mg drospirenone and 30 µg ethinyl-estradiol
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00871572
Drug: LY2409021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules by mouth taken once daily for 12 weeks
Trial: NCT00871572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules by mouth once daily for 12 weeks
Trial: NCT03165942
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02138396
Drug: Fentanyl Sublingual Spray (FSS)
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of fentanyl, 400 mcg per sublingual spray
Trial: NCT02138396
Drug: Fentanyl Citrate Injection (FCI)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of fentanyl citrate, 100 mcg per intramuscular injection
Trial: NCT01887106
Drug: GLPG1205 single ascending doses, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
Trial: NCT01887106
Drug: GLPG1205, multiple ascending doses, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
Trial: NCT01887106
Drug: Placebo, multiple ascending doses, oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses, daily for 14 days, oral suspension matching placebo
Trial: NCT03071380
Drug: Repatoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 10 mg rivaroxaban
Trial: NCT03846219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose.
Trial: NCT04320290
Drug: Direct Acting Antivirals
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of DAA treatment
Trial: NCT04066530
Drug: Mucosta tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosta tab. administered three times daily for two weeks
Trial: NCT01684891
Drug: RG1662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses of RG1662
Trial: NCT02905903
Drug: Tricholoacetic Acid (TCA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
Trial: NCT01705795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nacl four times over four months
Trial: NCT02244281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00749450
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00749450
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03469232
Drug: Huanglian-Jiedu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
Trial: NCT02454933
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg q2w (IV) infusion
Trial: NCT01565356
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 111 or 370MBq (3 or 10mCi), single dose
Trial: NCT00721071
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
Trial: NCT00055731
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03270839
Drug: Bonine 25Mg Chewable Tablet
RxNorm normalized name: BONINE 25mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motion sickness drug
Trial: NCT03270839
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active substance in the tablet
Trial: NCT00425321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for up to 12 weeks
Trial: NCT03927456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Trial: NCT02574598
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing interval of pembrolizumab can be increased in case of toxicity.
Trial: NCT00324220
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 Oral administration 3 times per week.
Trial: NCT02575833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a matching volume of placebo infused over approximately 60 minutes.
Trial: NCT00002897
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03290963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, dosed in units
Trial: NCT01835041
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01835041
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02254265
Drug: OTX-101 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX-101 0.05% Ophthalmic Solution
Trial: NCT02254265
Drug: OTX-101 0.09%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX-101 0.09% Ophthalmic Solution
Trial: NCT02254265
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of OTX-101 Ophthalmic Solution
Trial: NCT04530643
Drug: HY209 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 subjects will be assigned to drug (HY209 0.3% gel).
Trial: NCT04530643
Drug: HY209 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 subjects will be assigned to drug (HY209 0.5% gel).
Trial: NCT04530643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 subjects will be assigned to drug (Placebo).
Trial: NCT01547390
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03015246
Drug: Placebo stressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose
Trial: NCT00865761
Drug: XANAX XR® 3 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
Trial: NCT02101125
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01849965
Drug: DSC127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
Trial: NCT01849965
Drug: placebo vehicle gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01849965
Drug: Standard of Care gel, Aquasite
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00287586
Drug: Testosterone Gel (Androgel)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
Trial: NCT02102113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02640482
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT02640482
Drug: Placebo for ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03612921
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT02670616
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 IV day 1
Trial: NCT02670616
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 IV day 1
Trial: NCT02670616
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg per day on day 1-5
Trial: NCT00290550
Drug: MK0457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
Trial: NCT03162874
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT03162874
Drug: PXT002331 - dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03280264
Drug: KHK7580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT01153425
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants are clinically indicated for treatment.
Trial: NCT02262455
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
Trial: NCT04402411
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive morphine 0.1 mg/kg
Trial: NCT03027960
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg placebo for a 2-week period
Trial: NCT00985244
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
Trial: NCT02543944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose
Trial: NCT00172029
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04080739
Drug: ropivicaine 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
Trial: NCT03154125
Drug: Sayana® Press
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
Trial: NCT01867918
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02413229
Drug: DSXS1411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSXS (Taro Pharmaceuticals Inc.)
Trial: NCT02413229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Trial: NCT02955212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT04069819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01087359
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo